Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2023

Open Access 01-12-2023 | Alzheimer's Disease | Review

TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization: a specialized Tau perspective

Authors: Mahima Kapoor, Subashchandrabose Chinnathambi

Published in: Journal of Neuroinflammation | Issue 1/2023

Login to get access

Abstract

Microtubule-associated protein, Tau has been implicated in Alzheimer's disease for its detachment from microtubules and formation of insoluble intracellular aggregates within the neurons. Recent findings have suggested the expulsion of Tau seeds in the extracellular domain and their prion-like propagation between neurons. Transforming Growth Factor-β1 (TGF-β1) is a ubiquitously occurring cytokine reported to carry out immunomodulation and neuroprotection in the brain. TGF-β-mediated regulation occurs at the level of neuronal survival and differentiation, glial activation (astrocyte and microglia), amyloid production–distribution–clearance and neurofibrillary tangle formation, all of which contributes to Alzheimer's pathophysiology. Its role in the reorganization of cytoskeletal architecture and remodelling of extracellular matrix to facilitate cellular migration has been well-documented. Microglia are the resident immune sentinels of the brain responsible for surveying the local microenvironment, migrating towards the beacon of pertinent damage and phagocytosing the cellular debris or patho-protein deposits at the site of insult. Channelizing microglia to target extracellular Tau could be a good strategy to combat the prion-like transmission and seeding problem in Alzheimer's disease. The current review focuses on reaffirming the role of TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization and considers utilizing the approach of TGF-β-triggered microglia-mediated targeting of extracellular patho-protein, Tau, as a possible potential strategy to combat Alzheimer's disease.
Literature
1.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.CrossRefPubMed
2.
Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest. 2006;116:3060–9.CrossRefPubMedPubMedCentral
3.
Von Bernhardi R, Cornejo F, Parada G, Eugenin J. Role of TGFβ signaling in the pathogenesis of Alzheimer’s disease. Front Cell Neurosci. 2015;9:426.
4.
De Strooper B, Annaert W. Novel Research Horizons for Presenilins and γ-Secretases in Cell Biology and Disease. Annu Rev Cell Dev Biol. 2010;26:235–60.CrossRefPubMed
5.
6.
Sonawane SK, Chinnathambi S. Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer’s Disease: A Hypothesis. J Mol Neurosci. 2018;65:480–90.CrossRefPubMed
7.
8.
Medina M, Avila J. New perspectives on the role of tau in Alzheimer’s disease. Implications for therapy Biochem Pharmacol. 2014;88:540–7.CrossRefPubMed
9.
Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol. 2009;21:359–63.CrossRefPubMed
10.
Meraz-Ríos MA, Lira-De León KI, Campos-Peña V, De Anda-Hernández MA, Mena-López R. Tau oligomers and aggregation in Alzheimer’s disease. J Neurochem. 2010;112:1353–67.CrossRefPubMed
11.
Mocanu M-M, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, et al. The potential for -structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in Inducible Mouse Models of Tauopathy. J Neurosci. 2008;28:737–48.CrossRefPubMedPubMedCentral
12.
SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476–81.CrossRefPubMedPubMedCentral
13.
Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181:1426–35.CrossRefPubMedPubMedCentral
14.
15.
Gutierrez A, Vitorica J. Toward a New Concept of Alzheimer’s Disease Models: A Perspective from Neuroinflammation. J Alzheimers Dis JAD. 2018;64:S329–38.CrossRefPubMed
16.
17.
18.
Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909–13.CrossRefPubMedPubMedCentral
19.
20.
Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, et al. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun. 2017;5:99.CrossRefPubMedPubMedCentral
21.
Li L, Shi R, Gu J, Tung YC, Zhou Y, Zhou D, et al. Alzheimer’s disease brain contains tau fractions with differential prion-like activities. Acta Neuropathol Commun. 2021;9:28.CrossRefPubMedPubMedCentral
22.
Duyckaerts C, Clavaguera F, Potier M-C. The prion-like propagation hypothesis in Alzheimer’s and Parkinson’s disease. Curr Opin Neurol. 2019;32:266–71.CrossRefPubMed
23.
Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155–9.CrossRefPubMed
24.
Jaunmuktane Z, Brandner S. Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. Neuropathol Appl Neurobiol. 2020;46:522–45.CrossRefPubMedPubMedCentral
25.
26.
Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389–94.CrossRefPubMedPubMedCentral
27.
Lee WS, Tan DC, Deng Y, van Hummel A, Ippati S, Stevens C, et al. Syntaxins 6 and 8 facilitate tau into secretory pathways. Biochem J. 2021;478:1471–84.CrossRefPubMed
28.
Pilliod J, Desjardins A, Pernègre C, Jamann H, Larochelle C, Fon EA, et al. Clearance of intracellular tau protein from neuronal cells via VAMP8-induced secretion. J Biol Chem. 2020;295:17827–41.CrossRefPubMedPubMedCentral
29.
30.
Furman JL, Vaquer-Alicea J, White CL, Cairns NJ, Nelson PT, Diamond MI. Widespread tau seeding activity at early Braak stages. Acta Neuropathol (Berl). 2017;133:91–100.CrossRefPubMed
31.
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27:1592–9.CrossRefPubMed
32.
Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain. Nat Commun. 2015;6:8490.CrossRefPubMed
33.
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012;2:700.CrossRefPubMedPubMedCentral
34.
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841–5.CrossRefPubMedPubMedCentral
35.
Bachiller S, Jiménez-Ferrer I, Paulus A, Yang Y, Swanberg M, Deierborg T, et al. Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci. 2018;12:488.CrossRefPubMedPubMedCentral
36.
Das R, Chinnathambi S. Microglial priming of antigen presentation and adaptive stimulation in Alzheimer’s disease. Cell Mol Life Sci. 2019;76:3681–94.CrossRefPubMed
37.
Tang Y, Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol Neurobiol. 2016;53:1181–94.CrossRefPubMed
38.
De Biase LM, Schuebel KE, Fusfeld ZH, Jair K, Hawes IA, Cimbro R, et al. Local cues establish and maintain region-specific phenotypes of basal ganglia microglia. Neuron. 2017;95:341-356.e6.CrossRefPubMedPubMedCentral
39.
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer’s Disease. Cell. 2017;169:1276-1290.e17.CrossRefPubMed
40.
Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease. Nat Commun. 2020;11:6129.CrossRefPubMedPubMedCentral
41.
Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, et al. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 2017;21:366–80.CrossRefPubMedPubMedCentral
42.
Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao H, Gao T, et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease. Mol Neurodegener. 2018;13:24.CrossRefPubMedPubMedCentral
43.
Gerrits E, Brouwer N, Kooistra SM, Woodbury ME, Vermeiren Y, Lambourne M, et al. Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease. Acta Neuropathol (Berl). 2021;141:681–96.CrossRefPubMed
44.
45.
Chen Y, Colonna M. Microglia in Alzheimer’s disease at single-cell level. Are there common patterns in humans and mice? J Exp Med. 2021;218:e20202717.CrossRefPubMedPubMedCentral
46.
Sobue A, Komine O, Hara Y, Endo F, Mizoguchi H, Watanabe S, et al. Microglial gene signature reveals loss of homeostatic microglia associated with neurodegeneration of Alzheimer’s disease. Acta Neuropathol Commun. 2021;9:1.CrossRefPubMedPubMedCentral
47.
Navarro V, Sanchez-Mejias E, Jimenez S, Muñoz-Castro C, Sanchez-Varo R, Davila JC, et al. Microglia in Alzheimer’s Disease: Activated. Dysfunctional or Degenerative Front Aging Neurosci. 2018;10:140.CrossRefPubMedPubMedCentral
48.
49.
Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol. 2005;18:315–21.CrossRefPubMed
50.
Sheffield LG, Marquis JG, Berman NEJ. Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett. 2000;285:165–8.CrossRefPubMed
51.
52.
Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337–51.CrossRefPubMed
53.
Sonawane SK, Dubey T, Balmik AA, Das R, Chinnathambi S. Chapter 3. Alzheimer’s Disease Pathology: A Tau Perspective. In: Govindaraju T, editor. Alzheimers Dis Cambridge: Royal Society of Chemistry; 2022
54.
Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, et al. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. J Alzheimers Dis JAD. 2017;55:1083–99.CrossRefPubMed
55.
Wang C, Fan L, Khawaja RR, Liu B, Zhan L, Kodama L, et al. Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy. Nat Commun. 2022;13:1969.CrossRefPubMedPubMedCentral
56.
Bolós M, Llorens-Martín M, Perea JR, Jurado-Arjona J, Rábano A, Hernández F, et al. Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol Neurodegener. 2017;12:59.CrossRefPubMedPubMedCentral
57.
Biber K, Neumann H, Inoue K, Boddeke HWGM. Neuronal ‘On’ and ‘Off’ signals control microglia. Trends Neurosci. 2007;30:596–602.CrossRefPubMed
58.
Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of Tau pathology by the microglial Fractalkine receptor. Neuron. 2010;68:19–31.CrossRefPubMedPubMedCentral
59.
Chidambaram H, Das R, Chinnathambi S. Interaction of Tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation. Cell Biosci. 2020;10:109.CrossRefPubMedPubMedCentral
60.
Hopp SC, Lin Y, Oakley D, Roe AD, DeVos SL, Hanlon D, et al. The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer’s disease. J Neuroinflam. 2018;15:269.CrossRef
61.
Mondragón-Rodríguez S, Perry G, Zhu X, Moreira PI, Acevedo-Aquino MC, Williams S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer’s disease. Oxid Med Cell Longev. 2013;2013: 940603.CrossRefPubMedPubMedCentral
62.
Caraci F, Spampinato S, Sortino MA, Bosco P, Battaglia G, Bruno V, et al. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell Tissue Res. 2012;347:291–301.CrossRefPubMed
63.
64.
Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.CrossRefPubMed
65.
66.
67.
Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612–8.CrossRefPubMed
68.
Caraci F, Battaglia G, Bruno V, Bosco P, Carbonaro V, Giuffrida ML, et al. TGF-β1 pathway as a new target for neuroprotection in Alzheimer’s disease. CNS Neurosci Ther. 2009;17:237–49.CrossRefPubMedPubMedCentral
69.
Masliah E, Ho G, Wyss-Coray T. Functional role of TGF beta in Alzheimer’s disease microvascular injury: lessons from transgenic mice. Neurochem Int. 2001;39:393–400.CrossRefPubMed
70.
Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74:1200–5.CrossRefPubMedPubMedCentral
71.
Ueberham U, Ueberham E, Gruschka H, Arendt T. Altered subcellular location of phosphorylated Smads in Alzheimer’s disease. Eur J Neurosci. 2006;24:2327–34.CrossRefPubMed
72.
Kashima R, Hata A. The role of TGF-β superfamily signaling in neurological disorders. Acta Biochim Biophys Sin. 2017;50:106–20.CrossRefPubMedCentral
73.
Ueberham U, Hilbrich I, Ueberham E, Rohn S, Glöckner P, Dietrich K, et al. Transcriptional control of cell cycle-dependent kinase 4 by Smad proteins–implications for Alzheimer’s disease. Neurobiol Aging. 2012;33:2827–40.CrossRefPubMed
74.
Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000;57:1153.CrossRefPubMed
75.
Lee H, Ueda M, Zhu X, Perry G, Smith MA. Ectopic expression of phospho-Smad2 in Alzheimer’s disease: Uncoupling of the transforming growth factor-β pathway? J Neurosci Res. 2006;84:1856–61.CrossRefPubMed
76.
Cacquevel M, Lebeurrier N, Chéenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer’s disease. Curr Drug Targets. 2004;5:529–34.CrossRefPubMed
77.
Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer’s disease. Nature. 1997;389:603–6.CrossRefPubMed
78.
Kato T, Sekine Y, Nozaki H, Uemura M, Ando S, Hirokawa S, et al. Excessive production of transforming growth factor β1 causes mural cell depletion from cerebral small vessels. Front Aging Neurosci. 2020;12:151.CrossRefPubMedPubMedCentral
79.
Dickson MR, Perry RT, Wiener H, Go RCP. Association studies of transforming growth factor-beta 1 and Alzheimer’s disease. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2005;139B:38–41.CrossRef
80.
Bosco P, Ferri R, Salluzzo MG, Castellano S, Signorelli M, Nicoletti F, et al. Role of the transforming-growth-factor-β1 gene in late-onset Alzheimer’s disease: implications for the treatment. Curr Genomics. 2013;14:147–56.CrossRefPubMedPubMedCentral
81.
Fessel J. Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer’s disease. Alzheimers Dement Transl Res Clin Interv. 2019;5:899–905.CrossRef
82.
Fessel J. Prevention of Alzheimer’s disease by treating mild cognitive impairment with combinations chosen from eight available drugs. Alzheimers Dement N Y N. 2019;5:780–8.CrossRef
83.
Brionne TC, Tesseur I, Masliah E, Wyss-Coray T. Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron. 2003;40:1133–45.CrossRefPubMed
84.
Attaai A, Neidert N, von Ehr A, Potru PS, Zöller T, Spittau B. Postnatal maturation of microglia is associated with alternative activation and activated TGFβ signaling. Glia. 2018;66:1695–708.CrossRefPubMed
85.
86.
Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-β–dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131–43.CrossRefPubMed
87.
Neidert N, von Ehr A, Zöller T, Spittau B. Microglia-specific expression of Olfml3 Is directly regulated by transforming growth factor β1-induced Smad2 signaling. Front Immunol. 2018;9:1728.CrossRefPubMedPubMedCentral
88.
Spittau B, Dokalis N, Prinz M. The role of TGFβ signaling in microglia maturation and activation. Trends Immunol. 2020;41:836–48.CrossRefPubMed
89.
Kuroda E, Nishimura K, Kawanishi S, Sueyoshi M, Ueno F, Toji Y, et al. Mouse bone marrow-derived microglia-like cells secrete transforming growth factor-β1 and promote microglial Aβ phagocytosis and reduction of brain Aβ. Neuroscience. 2020;438:217–28.CrossRefPubMed
90.
Huang W-C, Yen F-C, Shie F-S, Pan C-M, Shiao Y-J, Yang C-N, et al. TGF-β1 blockade of microglial chemotaxis toward Aβ aggregates involves SMAD signaling and down-regulation of CCL5. J Neuroinflammation. 2010;7:28.CrossRefPubMedPubMedCentral
91.
Mocali A, Cedrola S, DellaMalva N, Bontempelli M, Mitidieri VM, Bavazzano A, et al. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol. 2004;39:1555–61.CrossRefPubMed
92.
Tichauer JE, Flores B, Soler B, Eugenín-von Bernhardi L, Ramírez G, von Bernhardi R. Age-dependent changes on TGFβ1 Smad3 pathway modify the pattern of microglial cell activation. Brain Behav Immun. 2014;37:187–96.CrossRefPubMed
93.
Floden AM, Combs CK. Microglia demonstrate age-dependent interaction with amyloid-β fibrils. J Alzheimers Dis JAD. 2011;25:279–93.CrossRefPubMed
94.
Akakura S, Singh S, Spataro M, Akakura R, Kim J-I, Albert ML, et al. The opsonin MFG-E8 is a ligand for the αvβ5 integrin and triggers DOCK180-dependent Rac1 activation for the phagocytosis of apoptotic cells. Exp Cell Res. 2004;292:403–16.CrossRefPubMed
95.
96.
Lim H, Yang T, Lee W, Park S-G. TGF-β Increases MFGE8 production in myeloid-derived suppressor cells to promote B16F10 melanoma metastasis. Biomedicines. 2021;9:896.CrossRefPubMedPubMedCentral
97.
Kim ES, Kim RS, Ren RF, Hawver DB, Flanders KC. Transforming growth factor-beta inhibits apoptosis induced by beta-amyloid peptide fragment 25–35 in cultured neuronal cells. Brain Res Mol Brain Res. 1998;62:122–30.CrossRefPubMed
98.
Prehn JH, Bindokas VP, Jordán J, Galindo MF, Ghadge GD, Roos RP, et al. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol. 1996;49:319–28.PubMed
99.
Ren RF, Flanders KC. Transforming growth factors-beta protect primary rat hippocampal neuronal cultures from degeneration induced by beta-amyloid peptide. Brain Res. 1996;732:16–24.CrossRefPubMed
100.
101.
Yu P, Wang H, Katagiri Y, Geller HM. An in vitro model of reactive astrogliosis and its effect on neuronal growth. Methods Mol Biol Clifton NJ. 2012;814:327–40.CrossRef
102.
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.CrossRefPubMedPubMedCentral
103.
104.
Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic analysis of reactive astrogliosis. J Neurosci Off J Soc Neurosci. 2012;32:6391–410.CrossRef
105.
106.
Grubman A, Chew G, Ouyang JF, Sun G, Choo XY, McLean C, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. Nat Neurosci. 2019;22:2087–97.CrossRefPubMed
107.
Burton T, Liang B, Dibrov A, Amara F. Transforming growth factor-beta-induced transcription of the Alzheimer beta-amyloid precursor protein gene involves interaction between the CTCF-complex and Smads. Biochem Biophys Res Commun. 2002;295:713–23.CrossRefPubMed
108.
Gray CW, Patel AJ. Regulation of beta-amyloid precursor protein isoform mRNAs by transforming growth factor-beta 1 and interleukin-1 beta in astrocytes. Brain Res Mol Brain Res. 1993;19:251–6.CrossRefPubMed
109.
Lesné S, Docagne F, Gabriel C, Liot G, Lahiri DK, Buée L, et al. Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem. 2003;278:18408–18.CrossRefPubMed
110.
Vivien D, Ali C. Transforming growth factor-β signalling in brain disorders. Cytokine Growth Factor Rev. 2006;17:121–8.CrossRefPubMed
111.
Zheng J-Y, Sun J, Ji C-M, Shen L, Chen Z-J, Xie P, et al. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer’s disease (APP/PS1) mice by inhibiting TGF-β/Smad2/STAT3 signaling. Neurobiol Aging. 2017;54:112–32.CrossRefPubMed
112.
Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139–50.CrossRefPubMedPubMedCentral
113.
Caraci F, Tascedda F, Merlo S, Benatti C, Spampinato SF, Munafò A, et al. Fluoxetine Prevents Aβ1-42-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-β1. Front Pharmacol. 2016;7:389.CrossRefPubMedPubMedCentral
114.
Pereira Diniz L, Tortelli V, Matias I, Morgado J, Bérgamo Araujo AP, Melo HM, et al. Astrocyte transforming growth factor beta 1 protects synapses against aβ oligomers in Alzheimer’s Disease Model. J Neurosci. 2017;37:6797–809.CrossRefPubMedCentral
115.
116.
Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782:197–228.CrossRefPubMed
117.
Derynck R, Miyazono K. The TGF-ß [beta] family. Cold Spring Harbor: Cold Spring Harbor laboratory press; 2008.
118.
Edlund S, Landström M, Heldin C-H, Aspenström P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell. 2002;13:902–14.CrossRefPubMedPubMedCentral
119.
Motizuki M, Saitoh M, Miyazawa K. Maid is a negative regulator of transforming growth factor-β-induced cell migration. J Biochem (Tokyo). 2015;158:435–44.CrossRefPubMed
120.
121.
122.
Walsh JE, Young MRI. TGF-beta regulation of focal adhesion proteins and motility of premalignant oral lesions via protein phosphatase 1. Anticancer Res. 2011;31:3159–64.PubMedPubMedCentral
123.
124.
Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–84.CrossRefPubMed
125.
de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev. 2004;15:1–11.CrossRefPubMed
126.
Vardouli L, Vasilaki E, Papadimitriou E, Kardassis D, Stournaras C. A novel mechanism of TGFbeta-induced actin reorganization mediated by Smad proteins and Rho GTPases. FEBS J. 2008;275:4074–87.CrossRefPubMed
127.
Hubchak SC, Runyan CE, Kreisberg JI, Schnaper HW. Cytoskeletal rearrangement and signal transduction in TGF-beta1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol JASN. 2003;14:1969–80.CrossRefPubMed
128.
Nalluri SM, O’Connor JW, Gomez EW. Cytoskeletal signaling in TGFβ-induced epithelial–mesenchymal transition. Cytoskeleton. 2015;72:557–69.CrossRefPubMed
129.
Vardouli L, Moustakas A, Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. J Biol Chem. 2005;280:11448–57.CrossRefPubMed
130.
Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001;12:27–36.CrossRefPubMedPubMedCentral
131.
Barcia C, Ros CM, Annese V, Carrillo-de Sauvage MA, Ros-Bernal F, Gómez A, et al. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep. 2012;2:809.CrossRefPubMedPubMedCentral
132.
133.
134.
Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia N Y N. 2004;6:603–10.CrossRef
135.
Chellaiah MA, Biswas RS, Yuen D, Alvarez UM, Hruska KA. Phosphatidylinositol 3,4,5-trisphosphate directs association of Src Homology 2-containing signaling proteins with gelsolin. J Biol Chem. 2001;276:47434–44.CrossRefPubMed
136.
Chellaiah MA, Soga N, Swanson S, McAllister S, Alvarez U, Wang D, et al. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem. 2000;275:11993–2002.CrossRefPubMed
137.
Varon C, Tatin F, Moreau V, Obberghen-Schilling EV, Fernandez-Sauze S, Reuzeau E, et al. Transforming growth factor β induces rosettes of podosomes in primary aortic endothelial cells. Mol Cell Biol. 2006;26:3582.CrossRefPubMedPubMedCentral
138.
Heneka MT, O’Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm Vienna Austria. 1996;2010(117):919–47.
139.
Chen J-H, Ke K-F, Lu J-H, Qiu Y-H, Peng Y-P. Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1-42-induced Alzheimer’s disease model rats. PLoS ONE. 2015;10: e0116549.CrossRefPubMedPubMedCentral
140.
Simard AR, Soulet D, Gowing G, Julien J-P, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron. 2006;49:489–502.CrossRefPubMed
141.
Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J Off Publ Fed Am Soc Exp Biol. 2004;18:998–1000.
142.
Kawanishi S, Takata K, Itezono S, Nagayama H, Konoya S, Chisaki Y, et al. Bone-Marrow-derived microglia-like cells ameliorate brain amyloid pathology and cognitive impairment in a mouse model of Alzheimer’s disease. J Alzheimers Dis JAD. 2018;64:563–85.CrossRefPubMed
143.
Kuroda E, Takata K, Nishimura K, Oka H, Sueyoshi M, Aitani M, et al. Peripheral blood-derived microglia-like cells decrease amyloid-β burden and ameliorate cognitive impairment in a mouse model of Alzheimer’s disease. J Alzheimers Dis JAD. 2020;73:413–29.CrossRefPubMed
144.
Avila J. The role of TGF-β1 in promoting microglial Aβ phagocytosis. Neuroscience. 2020;438:215–6.CrossRefPubMed
145.
Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H, Helfman DM. A critical role of tropomyosins in TGF-β regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell. 2004;15:4682–94.CrossRefPubMedPubMedCentral
146.
Morita T, Mayanagi T, Sobue K. Dual roles of myocardin-related transcription factors in epithelial–mesenchymal transition via slug induction and actin remodeling. J Cell Biol. 2007;179:1027–42.CrossRefPubMedPubMedCentral
147.
O’Connor JW, Gomez EW. Cell adhesion and shape regulate TGF-Beta1-induced epithelial-myofibroblast transition via MRTF-A Signaling. PLoS ONE. 2013;8:e83188.CrossRefPubMedPubMedCentral
148.
Masszi A, Di Ciano C, Sirokmány G, Arthur WT, Rotstein OD, Wang J, et al. Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol. 2003;284:F911-924.CrossRefPubMed
149.
Sebe A, Leivonen S-K, Fintha A, Masszi A, Rosivall L, Kähäri V-M, et al. Transforming growth factor-beta-induced alpha-smooth muscle cell actin expression in renal proximal tubular cells is regulated by p38beta mitogen-activated protein kinase, extracellular signal-regulated protein kinase1,2 and the Smad signalling during epithelial-myofibroblast transdifferentiation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2008;23:1537–45.
150.
Schneider D, Janshoff A. Inhibition of actin dynamics during epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2012;419:221–5.CrossRefPubMed
151.
Destaing O, Block MR, Planus E, Albiges-Rizo C. Invadosome regulation by adhesion signaling. Curr Opin Cell Biol. 2011;23:597–606.CrossRefPubMed
152.
Tumbarello DA, Turner CE. Hic-5 contributes to epithelial-mesenchymal transformation through a RhoA/ROCK-dependent pathway. J Cell Physiol. 2007;211:736–47.CrossRefPubMed
153.
Bianchi-Smiraglia A, Paesante S, Bakin AV. Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene. 2013;32:3049–58.CrossRefPubMed
154.
Mise N, Savai R, Yu H, Schwarz J, Kaminski N, Eickelberg O. Zyxin is a transforming growth factor-β (TGF-β)/Smad3 target gene that regulates lung cancer cell motility via integrin α5β1. J Biol Chem. 2012;287:31393–405.CrossRefPubMedPubMedCentral
155.
Mori M, Nakagami H, Koibuchi N, Miura K, Takami Y, Koriyama H, et al. Zyxin mediates actin fiber reorganization in epithelial-mesenchymal transition and contributes to endocardial morphogenesis. Mol Biol Cell. 2009;20:3115–24.CrossRefPubMedPubMedCentral
156.
157.
Tokuo H, Mabuchi K, Ikebe M. The motor activity of myosin-X promotes actin fiber convergence at the cell periphery to initiate filopodia formation. J Cell Biol. 2007;179:229–38.CrossRefPubMedPubMedCentral
158.
159.
Murray D, Horgan G, MacMathuna P, Doran P. NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer. Br J Cancer. 2008;99:1322–9.CrossRefPubMedPubMedCentral
160.
Battaglia RA, Delic S, Herrmann H, Snider NT. Vimentin on the move: new developments in cell migration. Research. 2018;7:1796.
161.
Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation. 2014;21:333–44.CrossRefPubMed
Metadata
Title
TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization: a specialized Tau perspective
Authors
Mahima Kapoor
Subashchandrabose Chinnathambi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2023
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-023-02751-8

Other articles of this Issue 1/2023

Journal of Neuroinflammation 1/2023 Go to the issue

Research

Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer’s disease-associated biomarkers alterations among de novo Parkinson’s disease patients: a prospective cohort study

Research

Topographic distribution of inflammation factors in a healing aneurysm

Research

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease

Research

Repeated mild traumatic brain injury causes sex-specific increases in cell proliferation and inflammation in juvenile rats

Review

Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis

Research

Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis